

ARZERRA (ofatumumab)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patients must have **ONE** of the following:

1. Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

AND ONE of the following:

- a. Previously untreated patients
 - i. Used in combination with chlorambucil in previously untreated patients
- b. Relapsed or refractory
 - i. Used in combination with flurdarabine and cyclophosphamide
- c. Extended treatment in patients
 - i. Complete or partial response after 2 previous therapies for recurrent or progressive CLL /SLL
- 2. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma
 - a. Refractory or intolerant to rituximab

AND the following:

1. Hepatitis B virus screening before initiating treatment

Prior - Approval Limits

Duration 6 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnoses

Patients must have **ONE** of the following:

- 1. Chronic Lymphocytic Leukemia
- 2. Small Lymphocytic Lymphoma
- 3. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma



ARZERRA (ofatumumab)

AND the following:

1. NO disease progression or unacceptable toxicity

Prior – Approval Renewal Limits Duration 12 months